Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management

Ipilimumab plus nivolumab (Ipi/Nivo) has revolutionized advanced renal cell carcinoma (RCC) treatment. However, it encompassed fatal immune-related adverse events (irAEs). Myocarditis with concomitant myasthenia gravis (MG) has a mortality rate of 50%, and a high dose of methylprednisolone (mPSL) sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanase, Takahiro, Moritoki, Yoshinobu, Kondo, Hajime, Ueyama, Daigo, Akita, Hidetoshi, Yasui, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726655/
https://www.ncbi.nlm.nih.gov/pubmed/33318935
http://dx.doi.org/10.1016/j.eucr.2020.101508
_version_ 1783620927884361728
author Yanase, Takahiro
Moritoki, Yoshinobu
Kondo, Hajime
Ueyama, Daigo
Akita, Hidetoshi
Yasui, Takahiro
author_facet Yanase, Takahiro
Moritoki, Yoshinobu
Kondo, Hajime
Ueyama, Daigo
Akita, Hidetoshi
Yasui, Takahiro
author_sort Yanase, Takahiro
collection PubMed
description Ipilimumab plus nivolumab (Ipi/Nivo) has revolutionized advanced renal cell carcinoma (RCC) treatment. However, it encompassed fatal immune-related adverse events (irAEs). Myocarditis with concomitant myasthenia gravis (MG) has a mortality rate of 50%, and a high dose of methylprednisolone (mPSL) should be administered with careful attention to MG exacerbation. We present the case of a 59-year-old man with progressing lung metastasis of RCC. After one cycle of Ipi/Nivo, he experienced myocarditis and MG, managed by mPSL pulse therapy, plasma exchange, and high-dose intravenous immunoglobulin. We share the therapeutic course, aiming to contribute to the limited literature on rare but aggressive irAEs.
format Online
Article
Text
id pubmed-7726655
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-77266552020-12-13 Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management Yanase, Takahiro Moritoki, Yoshinobu Kondo, Hajime Ueyama, Daigo Akita, Hidetoshi Yasui, Takahiro Urol Case Rep Oncology Ipilimumab plus nivolumab (Ipi/Nivo) has revolutionized advanced renal cell carcinoma (RCC) treatment. However, it encompassed fatal immune-related adverse events (irAEs). Myocarditis with concomitant myasthenia gravis (MG) has a mortality rate of 50%, and a high dose of methylprednisolone (mPSL) should be administered with careful attention to MG exacerbation. We present the case of a 59-year-old man with progressing lung metastasis of RCC. After one cycle of Ipi/Nivo, he experienced myocarditis and MG, managed by mPSL pulse therapy, plasma exchange, and high-dose intravenous immunoglobulin. We share the therapeutic course, aiming to contribute to the limited literature on rare but aggressive irAEs. Elsevier 2020-11-28 /pmc/articles/PMC7726655/ /pubmed/33318935 http://dx.doi.org/10.1016/j.eucr.2020.101508 Text en © 2020 The Authors. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Yanase, Takahiro
Moritoki, Yoshinobu
Kondo, Hajime
Ueyama, Daigo
Akita, Hidetoshi
Yasui, Takahiro
Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management
title Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management
title_full Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management
title_fullStr Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management
title_full_unstemmed Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management
title_short Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management
title_sort myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: a case report of successful management
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726655/
https://www.ncbi.nlm.nih.gov/pubmed/33318935
http://dx.doi.org/10.1016/j.eucr.2020.101508
work_keys_str_mv AT yanasetakahiro myocarditisandmyastheniagravisbycombinednivolumabandipilimumabimmunotherapyforrenalcellcarcinomaacasereportofsuccessfulmanagement
AT moritokiyoshinobu myocarditisandmyastheniagravisbycombinednivolumabandipilimumabimmunotherapyforrenalcellcarcinomaacasereportofsuccessfulmanagement
AT kondohajime myocarditisandmyastheniagravisbycombinednivolumabandipilimumabimmunotherapyforrenalcellcarcinomaacasereportofsuccessfulmanagement
AT ueyamadaigo myocarditisandmyastheniagravisbycombinednivolumabandipilimumabimmunotherapyforrenalcellcarcinomaacasereportofsuccessfulmanagement
AT akitahidetoshi myocarditisandmyastheniagravisbycombinednivolumabandipilimumabimmunotherapyforrenalcellcarcinomaacasereportofsuccessfulmanagement
AT yasuitakahiro myocarditisandmyastheniagravisbycombinednivolumabandipilimumabimmunotherapyforrenalcellcarcinomaacasereportofsuccessfulmanagement

Ejemplares similares